Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients.
COX acetylation
colorectal adenomas
cyclooxygenases
familial adenomatous polyposis
platelets
prostaglandin E2
thromboxane
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
received:
27
03
2023
revised:
21
04
2023
accepted:
23
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
The results of Aspirin prevention of colorectal adenomas in patients with familial adenomatous polyposis (FAP) are controversial. We conducted a biomarker-based clinical study in eight FAP patients treated with enteric-coated low-dose Aspirin (100 mg daily for three months) to explore whether the drug targets mainly platelet cyclooxygenase (COX)-1 or affects extraplatelet cellular sources expressing COX-isozymes and/or off-target effects in colorectal adenomas. In FAP patients, low-dose Aspirin-acetylated platelet COX-1 at Serine529 (>70%) was associated with an almost complete inhibition of platelet thromboxane (TX) B Although low-dose Aspirin appropriately inhibited the platelet, persistently high systemic TXA
Sections du résumé
BACKGROUND
BACKGROUND
The results of Aspirin prevention of colorectal adenomas in patients with familial adenomatous polyposis (FAP) are controversial.
METHODS
METHODS
We conducted a biomarker-based clinical study in eight FAP patients treated with enteric-coated low-dose Aspirin (100 mg daily for three months) to explore whether the drug targets mainly platelet cyclooxygenase (COX)-1 or affects extraplatelet cellular sources expressing COX-isozymes and/or off-target effects in colorectal adenomas.
RESULTS
RESULTS
In FAP patients, low-dose Aspirin-acetylated platelet COX-1 at Serine529 (>70%) was associated with an almost complete inhibition of platelet thromboxane (TX) B
CONCLUSIONS
CONCLUSIONS
Although low-dose Aspirin appropriately inhibited the platelet, persistently high systemic TXA
Identifiants
pubmed: 37173923
pii: cancers15092457
doi: 10.3390/cancers15092457
pmc: PMC10177499
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG2017-ID 20365
Organisme : Instituto de Salud Carlos III
ID : PI14/01218
Organisme : Instituto de Salud Carlos III
ID : PI17/01109
Organisme : European Union
ID : European Social Fund - PON Research and Innovation 2014-2020
Références
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638469
Mol Cell Proteomics. 2012 Apr;11(4):M111.010587
pubmed: 22186715
J Cell Sci. 2016 May 1;129(9):1831-42
pubmed: 26966188
J Pharmacol Exp Ther. 2012 Apr;341(1):242-50
pubmed: 22262921
Br J Cancer. 2014 Jul 8;111(1):61-7
pubmed: 24874482
Nat Commun. 2017 Feb 09;8:14344
pubmed: 28181495
Int J Colorectal Dis. 1997;12(1):9-13
pubmed: 9112143
Lancet. 2009 May 30;373(9678):1849-60
pubmed: 19482214
Orphanet J Rare Dis. 2009 Oct 12;4:22
pubmed: 19822006
Clin Pharmacol Ther. 2017 Jul;102(1):52-61
pubmed: 28139830
J Am Coll Cardiol. 2022 Jul 19;80(3):233-250
pubmed: 35660296
Cancer Prev Res (Phila). 2011 May;4(5):655-65
pubmed: 21543343
J Clin Invest. 1975 Sep;56(3):624-32
pubmed: 1159076
Science. 1992 May 1;256(5057):668-70
pubmed: 1350108
Biochem Biophys Res Commun. 1999 Jul 14;260(3):609-13
pubmed: 10403814
Diabetes Metab Syndr Obes. 2021 Sep 07;14:3831-3837
pubmed: 34522109
Biochem Pharmacol. 2020 Aug;178:114094
pubmed: 32535107
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):474-481
pubmed: 33812492
J Clin Invest. 2018 Jul 2;128(7):2732-2742
pubmed: 29733297
Cell. 1996 Nov 29;87(5):803-9
pubmed: 8945508
J Thromb Haemost. 2014 Aug;12(8):1320-30
pubmed: 24942808
Anticancer Res. 2021 Jan;41(1):429-436
pubmed: 33419840
Oncogene. 2010 Feb 11;29(6):781-8
pubmed: 19946329
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4
pubmed: 7576992
J Biol Chem. 1994 May 6;269(18):13207-15
pubmed: 8175750
Thromb Res. 1980 Feb 1-15;17(3-4):317-27
pubmed: 7368167
J Clin Invest. 2006 Jan;116(1):4-15
pubmed: 16395396
Cancer Res. 2021 Jul 15;81(14):3751-3761
pubmed: 33893087
Cancer Prev Res (Phila). 2013 Jun;6(6):507-10
pubmed: 23636051
Cancer J. 2013 Nov-Dec;19(6):502-10
pubmed: 24270349
Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):607-22
pubmed: 22122775
Pharmacol Res. 2021 Aug;170:105744
pubmed: 34182131
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16830-5
pubmed: 25385584
Nat Protoc. 2016 Apr;11(4):795-812
pubmed: 27010757
Circulation. 2004 Mar 30;109(12):1468-71
pubmed: 15037526
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:483-93
pubmed: 12432938
J Lipid Res. 2015 Aug;56(8):1386-402
pubmed: 25838312
Fam Cancer. 2006;5(3):221-6
pubmed: 16998667
EBioMedicine. 2015 Feb 1;2(2):165-171
pubmed: 25750933
Pharmacol Res. 2022 Nov;185:106506
pubmed: 36241001
Am J Gastroenterol. 2006 Feb;101(2):385-98
pubmed: 16454848
J Pharmacol Exp Ther. 2019 Sep;370(3):416-426
pubmed: 31248980
J Biol Chem. 2005 Jan 28;280(4):3112-20
pubmed: 15548519
Biochim Biophys Acta. 2013 Aug;1830(8):4160-70
pubmed: 23562554
Dig Dis Sci. 1998 Feb;43(2):311-6
pubmed: 9512123
J Clin Lab Anal. 2022 May;36(5):e24356
pubmed: 35318741
Acta Gastroenterol Belg. 2011 Sep;74(3):421-6
pubmed: 22103048
Int J Mol Sci. 2020 May 18;21(10):
pubmed: 32443623
J Clin Invest. 1994 Feb;93(2):493-8
pubmed: 8113389
Cancer Res. 2002 Jan 1;62(1):63-6
pubmed: 11782360